Net Loss of Piramal Pharma reported to Rs 88.64 crore in the quarter ended June 2024 as against net loss of Rs 98.58 crore during the previous quarter ended June 2023. Sales rose 11.57% to Rs 1951.14 crore in the quarter ended June 2024 as against Rs 1748.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales1951.141748.85 12 OPM %10.487.57 - PBDT139.4766.50 110 PBT-45.08-107.11 58 NP-88.64-98.58 10 Powered by Capital Market - Live News

Piramal Pharma has granted 48,30,836 stock options under Employee Stock Option and Incentive Plan on 26 July 2024. Powered by Capital Market - Live News

Piramal Pharma will hold a meeting of the Board of Directors of the Company on 26 July 2024.Powered by Capital Market - Live News

Piramal Pharma announced that the Annual General Meeting (AGM) of the company will be held on 26 July 2024.Powered by Capital Market - Live News

Piramal Pharma has fixed 12 July 2024 as record date for the purpose of determining the members eligible for final dividend for the financial year ended 31 March 2024. Powered by Capital Market - Live News